These anti-cancer medicines work by inhibiting TOP2’s DNA religation function, which stabilizes the TOP2-DNA covalent complex and ultimately leads to the destruction of TOP2cc by 26 S proteasome. This evidence concerns the gene TOP2A and cancer.